版本:
中国

BRIEF-Allergan issues statement on Namenda XR patent litigation following announcement of ANDA approvals

Sept 29 Allergan Plc

* Company has not announced any earlier licensed entry dates

* Company has settled with all other Namenda XR ANDA defendants, including Lupin Limited and Lupin Pharmaceuticals Inc

* If district court ruling on patents is upheld, there is a possibility that generic entry for Namenda XR could occur

* Company will defend validity of the patents on appeal and believes that its arguments on appeal are substantial and meritorious Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐